Treatment

Epcoritamab (GEN3013) clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedPhase I and Phase II (Integrated)- Other
HOVON 178 WM: A prospective phase I/II trial of epcoritamab in patients with relapsed or refractory Waldenstrom’s macroglobulinemia
This study is testing a new medicine called epcoritamab for people with a type of blood cancer called Waldenstrom’s macroglobulinemia. It's for patients whose cancer has come back or hasn't responded to other treatments. The aim is to see if the medicine is safe and helps shrink the cancer.
For: relapsed or refractory Waldenstrom’s macroglobulinemia
Denmark · Belgium · Netherlands